Molecular Targeted Therapy

"Molecular Targeted Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.

Descriptor ID	D058990
MeSH Number(s)	E02.319.574
Concept/Terms	Molecular Targeted Therapy Molecular Targeted Therapy Molecular Targeted Therapies Targeted Therapies, Molecular Targeted Therapy, Molecular Therapies, Molecular Targeted Therapy, Molecular Targeted Targeted Molecular Therapy Molecular Therapies, Targeted Molecular Therapy, Targeted Targeted Molecular Therapies Therapies, Targeted Molecular Therapy, Targeted Molecular

Below are MeSH descriptors whose meaning is more general than "Molecular Targeted Therapy".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Therapeutics [E02]
Drug Therapy [E02.319]
Molecular Targeted Therapy [E02.319.574]

Below are MeSH descriptors whose meaning is more specific than "Molecular Targeted Therapy".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Molecular Targeted Therapy" by people in this website by year, and whether "Molecular Targeted Therapy" was a major or minor topic of these publications.

Bar chart showing 100 publications over 15 distinct years, with a maximum of 14 publications in 2015

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2010	1	2	3
2011	0	7	7
2012	2	3	5
2013	0	3	3
2014	3	4	7
2015	2	12	14
2016	3	10	13
2017	3	7	10
2018	1	5	6
2019	2	8	10
2020	1	4	5
2021	2	4	6
2023	0	1	1
2024	1	6	7
2025	1	2	3

Below are the most recent publications written about "Molecular Targeted Therapy" by people in Profiles.

Vijay V, Karisani N, Shi L, Hung YH, Vu P, Kattel P, Kenney L, Merritt J, Adil R, Wu Q, Zhen Y, Morris R, Kreuzer J, Kathiresan M, Herrera Lopez XI, Ellis H, Gritti I, Lecorgne L, Farag I, Popa A, Shen W, Kato H, Xu Q, Balasooriya ER, Wu MJ, Wan J, Kondo H, Chaturantabut S, Raghavan S, Hall MD, Patnaik S, Shen M, Kelley RK, Cleary JM, Lawrence MS, Root DE, Patra KC, Silveira VS, Benes CH, Deshpande V, Juric D, Sellers WR, Ferrone CR, Haas W, Vazquez F, Getz G, Bardeesy N. Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets. Cancer Discov. 2025 Sep 04; 15(9):1858-1882.

View in: PubMed
Shen H, Liangpunsakul S, Iwakiri Y, Szabo G, Wang H. Immunological mechanisms and emerging therapeutic targets in alcohol-associated liver disease. Cell Mol Immunol. 2025 Oct; 22(10):1190-1204.

View in: PubMed
Winthrop KL, Bathon J, Kerschbaumer A, Isaacs JD, Mease P, Gottenberg JE, Crow MK, Kay J, Crofford L, Baraliakos X, Bykerk V, Siebert S, Kloppenburg M, Aletaha D, McInnes IB, Huizinga T, Voll R, Gravallese EM, Breedveld FC, van Vollenhoven R, Smolen JS. Chasing the target: reports from the Advances in Targeted Therapies meeting, 2024. Ann Rheum Dis. 2025 Jun; 84(6):927-936.

View in: PubMed
Avelino ARM, Pulipati S, Jamouss K, Bhardwaj PV. Updates in Treatment of HER2-positive Metastatic Breast Cancer. Curr Treat Options Oncol. 2024 Dec; 25(12):1471-1481.

View in: PubMed
Bhardwaj PV, Abdou Y. Navigating Treatment Pathways in Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies. J Clin Oncol. 2024 Dec; 42(34):4012-4017.

View in: PubMed
Leylek O, Honeywell ME, Lee MJ, Hemann MT, Ozcan G. Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy. Gastric Cancer. 2024 Nov; 27(6):1201-1219.

View in: PubMed
Huck DM, Buckley LF, Chandraker A, Blankstein R, Weber B. Targeting Pharmacotherapies for Inflammatory and Cardiorenal Endpoints in Kidney Disease. J Cardiovasc Pharmacol. 2024 06 01; 83(6):511-521.

View in: PubMed
Yaniv B, Tanenbaum B, Kazakova V, Patel SA. Translational insights into the genetics and immunobiology of relapsed/refractory follicular lymphoma. Leuk Res. 2024 Jul; 142:107519.

View in: PubMed
Delva C, Pearson TF, Harris JE. Advancements in Targeted Therapies for Vitiligo: Prioritizing Equity in Drug Development. Cutis. 2024 Apr; 113(4):156-158.

View in: PubMed
Mittal K, Joshi M. FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape. Med. 2024 Mar 08; 5(3):176-178.

View in: PubMed

People

Explore

Similar Concepts

Top Journals